FDA seeks advice on opioid-induced constipation drugs’ risks
This article was originally published in Scrip
Executive Summary
The FDA is convening a panel of its outside advisers over two days on 11-12 June to help the agency flesh out whether to require cardiovascular outcomes trials (CVOTs) for all, only specific or none of the peripherally active mu opioid receptor antagonists being developed to treat opioid-induced constipation (OIC) in patients with chronic non-cancer pain.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.